Miltenyi Biotec

Bergisch Gladbach, Germany
Find alternatives to Miltenyi Biotec for CAR-T →
8 confirmed programs · 8 sponsors · Last scored 2026-10-29
73.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (8) ○ SEC Filings ✓ Press (16) ✓ EMA GMP (2) ○ MHRA GMP ✓ HC GMP (1)

Quick Facts: Miltenyi Biotec

Signal Score
73.0/100 (as of 2026-10-29)
Quality Compliance
100.0/100
Headquarters
Bergisch Gladbach, Germany
Modalities
CAR-T, Cell Therapy
Active Programs
8 confirmed from ClinicalTrials.gov across 8 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Miltenyi Biotec

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA InspectionsNo US records on file
EMA GMP Certificates2 on record
Most Recent HC OutcomeCompliant · 2018-03-21
HC Attribution1 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations 57.5
8 active programs across 8 sponsors
Modalities: CAR-T, Cell Therapy
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 8 sponsors · Modalities: CAR-T, Cell Therapy · 2 programs in advanced phases (Phase 2/3)
Programs 8
Sponsors8
ModalitiesCAR-T, Cell Therapy
8 active programs across 8 sponsors
Modalities: CAR-T, Cell Therapy
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease PHASE1 Recruiting
NCT05705570 Clinical Trial Using CAR- T Cells for Treatment of Patients... PHASE1 Recruiting
NCT05094206 CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies PHASE1 Terminated
NCT05281809 Local Manufacture of CAR T-Cell Products for the Treatment of... PHASE2 Recruiting
NCT04464434 Upfront Autologous HSCT Versus Immunosuppression in Early... PHASE4 Completed
NCT01033617 IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem... NA Completed
NCT00595127 Hematopoietic Stem Cell Transplantation for Treatment of... NA Completed
NCT01881334 Expanded Access to T-cell Depleted Haplo-Identical Stem Cells... NA Available
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Bergisch Gladbach, DE
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Bergisch Gladbach, DE
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals16 articles (not scored)
1 manufacturing site: Bergisch Gladbach, DE
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

Miltenyi Biotec EMA GMP Compliance 2 certificates

2025-06
2024-09
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_NW_04_GMP_2025_0046 Miltenyi Biotec B.V. & Co. KG Germany 2025-06-18 COMPLIANT
DE_MV_01_GMP_2025_0017 Miltenyi Biotec B.V. & Co. KG Germany 2024-09-19 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 16 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-05-06
GMP Cytokines Market Key Players | Miltenyi Biotec, ABCAM, Akron Biotech, REPROCELL Inc etc. - openPR.com
GMP Cytokines Market Key Players | Miltenyi Biotec, ABCAM, Akron Biotech, REPROCELL Inc etc.  openPR.com
partnership 2026-04-28
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing - koreabiomed.com
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing  koreabiomed.com
partnership 2026-04-28
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ  Chosunbiz
partnership 2026-04-28
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy - aju press
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy  aju press
partnership 2026-04-28
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ  Chosunbiz
partnership 2026-04-27
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform - Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform  Manufacturing Chemist
partnership 2026-04-27
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform - Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform  Manufacturing Chemist
regulatory 2026-04-26
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
regulatory 2026-04-26
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
regulatory 2026-04-25
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
regulatory 2026-04-24
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
regulatory 2026-04-18
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
regulatory 2026-04-14
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
general 2026-02-23
Miltenyi Biotec sprints for the CAR-T finish line amid rising Big Pharma consolidation - ET Pharma
Miltenyi Biotec sprints for the CAR-T finish line amid rising Big Pharma consolidation  ET Pharma
general 2026-02-20
Miltenyi Biotec weighs local CGT manufacturing, eyes export potential - Business Standard
Miltenyi Biotec weighs local CGT manufacturing, eyes export potential  Business Standard
regulatory 2026-02-20
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies - Moneycontrol.com
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies  Moneycontrol.com

Frequently Asked Questions About Miltenyi Biotec

Does Miltenyi Biotec hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 EMA GMP certificates for Miltenyi Biotec.
How many clinical programs is Miltenyi Biotec linked to?
Miltenyi Biotec is associated with 8 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Miltenyi Biotec's CDMO Signal Score?
Miltenyi Biotec has a Signal Score of 73/100, based on quality, operations, financial stability, and capacity data.
Evaluating Miltenyi Biotec for a manufacturing program?
Use the free AI matchmaker to compare Miltenyi Biotec against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Cellex Cell Professionals
Cologne, Germany
Signal Score: 59.0
Cell Therapy, CAR-T
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy

Compare Miltenyi Biotec with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Miltenyi Biotec
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.